Elicio Therapeutics Inc. is using precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and solid tumors. Founded in 2011, the company has developed an innovative pipeline of cancer immunotherapies addressing critical unmet needs.
Three vaccine candidates are currently in Elicio Therapeutics’ pipeline: ELI-002, ELI-007 and ELI-008.
